Loading...

News List

FDA加速批准其布鲁顿氏激酶抑制剂Jaypirca上市

2023-02-01


FDA加速批准其布鲁顿氏激酶抑制剂Jaypirca上市

2023获批第一款含氟药物。2023.01.27, 礼来(Eli Lilly)旗下的Loxo Oncology宣布,FDA加速批准其布鲁顿氏激酶(BTK)抑制剂Jaypirca(pirtobrutinib)上市,用于既往接受过至少2线系统治疗的复发或难治性套细胞淋巴瘤(MCL)成人患者,这些患者经过包含BTK抑制剂在内的既往治疗 (Jaypirca是FDA批准的首个也是目前唯一一款非共价可逆性BTK抑制剂)。

Pre: PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials

Next: The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.